Loading…
Loading…
I wanted to get a sense from you guys as to what voids you think you need to fill
I wanted to see if you had any color on patients switching from Descovy versus those who are brand new to PrEP
I wasn't sure what drives the investment priorities, whether it's the drug or the indication, and if there's a clear path to labeling claim
would you characterize it as more consumer-centric through LillyDirect? Or should we think about it as a more typical pharma launch with PBM and payer negotiations being really critical on day 1
can you talk about how the GI adverse event rates changed over the course of the studies?
Would these be a tipping point on broader reimbursement or access? I mean it's clear you have a benefit there